• The ChemoStart program is an initiative led by Leandro Sigman along with nearly thirty mentors and health experts.

Madrid, October 4, 2024 – Insud Pharma, the global pharmaceutical group, has officially opened the eighth edition of ChemoStart, its flagship program designed to support startups in the health sector. ChemoStart aims to accelerate startups with innovative health projects, offering crucial mentoring and health project assistance. This year, the program goes internationally, allowing health startups from around the world to participate.

This opportunity is open to initiatives in fields such as new drugs, diagnostics, artificial intelligence, biotechnology, digital health, and personalized medicine. The key is that the proposed solution must be disruptive and solve a critical health challenge. Selected startups will receive at least six months of startup mentoring and guidance from health and business experts.

Selected projects will receive advice from a panel of experts, at least six months of support. Insud Pharma will also act as an investor in projects that align with its strategic lines of activity.

The application period closes on November 22. After that, each proposal will be carefully reviewed, and shortlisted applicants will be invited to present their ideas at a Pitch Day in Madrid in January 2025. The innovative projects will be assessed by an external panel of experts from various fields of entrepreneurship and health.

Entrepreneurs and health or biomedicine startups wishing to present their innovative projects can apply directly through this link.

This initiative aims to promote innovative and disruptive solutions that enhance health and well-being, led by Leandro Sigman and supported by nearly thirty mentors from different health sectors.

ChemoStart is a global program by Insud Pharma that helps accelerate startups and companies with innovative health and medical care projects. Insud Pharma is a Spanish company recognized in the pharmaceutical and health sector with over 45 years of history. It employs around 9,000 people in 50 countries and makes a significant contribution to global public health through the medications and active ingredients it develops and produces through its three synergistic units: industrial (Chemo), brand (Exeltis), and biotechnology (mAbxience and Algenex).